Stocks
Vaxart Sets Early 2027 Efficacy Readout, Q2 Sentinel Data Release Imminent
Vaxart (VXRT) anticipates a primary efficacy readout for its oral vaccine platform in early 2027, with a Q2 sentinel data release expected...
#biotechnology 6 articles
Stocks
Recursion Projects 2028 Runway, Holds 2026 Expenses Below $390M
Recursion Pharmaceuticals projects its operational runway into early 2028 while committing to keep 2026 cash operating expenses under $390 million, driven by...
Stocks
Quantum BioPharma Taps Senergy, King Tide for Investor Outreach
Quantum BioPharma Ltd. has engaged Senergy Communications Capital Inc. and King Tide Media LLC for a one-month contract to bolster investor awareness...
Markets
Eli Lilly’s Diversification Offers Stronger Investment Case
Beyond its weight-loss drug success, Eli Lilly's robust pipeline across oncology, immunology, and neuroscience presents a compelling investment thesis.
Markets
Sartorius Stedim Biotech Posts Q1 Profit Growth, Reaffirms FY26 Outlook
Sartorius Stedim Biotech reported a rise in Q1 profit and revenue, driven by its consumables business, and confirmed its fiscal 2026 financial...
Stocks
Enveric Biosciences Secures Up to $13.9 Million in Private Placement
Enveric Biosciences announced a private placement expected to raise up to $13.9 million, with $5 million upfront and potential additional proceeds from...